藥物股繼續跑贏大市 多隻未有盈利生物股飆升9%-61%破頂
市場憂慮全球出現第二波新冠肺炎疫情,醫藥板塊近日明顯跑贏大市,尤其是多隻未有盈利的生物股急漲兼部份股價破頂,其中專注於治療癌症和自身免疫性疾病新藥及生物類似的研發和生產商邁博藥業-B(02181.HK)一舉升破去年5月上市價1.5%及去年6月所創上市高位1.51元,最高見1.74元,現造1.6元,飆升近62%,一向稀疏薄成交急增至296萬股創今年新高。
去年底才上市的康寧傑瑞製藥-B(09966.HK)三連揚,今早股價升破2月所創上市高位20.65元,最高見22.45元,報22.4元,續漲14%。康希諾生物-B(06185.HK)連續第五天創上市新高,最高見226元,現造222.4元,續漲13%。上海君實生物醫藥-B(01877.HK)升破本月初所創上市高位42元,最高見42.95元,現造42.9元,漲9.2%。
華領醫藥-B(02552.HK)延續上周連日強勢,今早股價曾重越牛熊線(5.55元),最高見5.7元,創逾半年高,現造5.36元,續漲20%。
諾誠健華-B(09969.HK)、中國抗體製藥-B(03681.HK)及歌禮製藥-B(01672.HK)依次升逾3%-7%,今年3月才上市的前者高見16.36元屢創上市新高。
藍籌中生製藥(01177.HK)及藥明生物(02269.HK)反覆續升2.3%-4%,前者高見12.3元,後者高見140.7再創上市新高。
恆指及國指分別扭四連跌及兩兩連跌,今天反覆微彈0.5%,分別報23,922及9,722,成交額561億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.